Food and Drug Administration Commissioner Marty Makary resigned Tuesday after months of friction with President Trump over flavored e-cigarette approvals, capping a turbulent tenure that drew fire from vaping advocates, pharmaceutical executives, and pro-life leaders alike.
Trump confirmed the departure as he left the White House en route to China for a summit with Xi Jinping. He declined to say whether he fired Makary outright.
"He's a great doctor... [but] he was having some difficulty," Trump told reporters, adding that Makary was "going to go on and live a good life." The remark came after nearly a week of reports that Trump had approved Makary's termination.
The immediate trigger was Makary's handling, or mishandling, of a fruit-flavored vape product from California manufacturer Glas. In December, the FDA's own website announced approval of the company's flavored vapes, including mango. The product uses Bluetooth technology to verify users are at least 21, an "age-gated" system that requires scanning an ID to unlock nicotine-laced vapor.
Yet Makary blocked implementation of that approval for months. Trump, who had promised during his successful 2024 presidential campaign to support executives in the vape industry, directly reprimanded Makary last week over the delay. Only after the president's intervention did the agency finally move forward with the approval.
On Friday, the FDA went further, announcing plans to relax enforcement against e-cigarette makers with pending product applications. By Tuesday, Makary was gone.
The sequence tells the story. The FDA commissioner approved a product on paper, then sat on it. The president stepped in. The agency reversed course. And the commissioner walked out the door.
Vaping was not the only front. Administration officials told the New York Post they were infuriated that Makary had met with, provided funding to, and hired subordinates associated with what they viewed as left-leaning causes. The former Johns Hopkins cancer surgeon had regularly appeared alongside Trump over the past year at events promoting public health initiatives and lower prescription drug prices. But behind the scenes, the relationship frayed.
The Washington Times reported that Makary plans to formally leave Thursday, with Kyle Diamantas, the FDA's deputy commissioner for food, set to lead the agency on an acting basis. Trump said a permanent replacement would be found.
This resignation fits a pattern of abrupt personnel moves inside the administration when officials fail to execute the president's agenda.
Sen. Josh Hawley (R-Mo.) wasted no time. In a post on X Tuesday, Hawley delivered a blistering assessment that went well beyond the vaping dispute.
"Dr. Makary was uniquely destructive to the prolife movement. He attempted to place pro-abortion lawyers in key positions. He slow walked a vitally necessary review of the abortion drug mifepristone. He used his discretion to approve a new abortion drug when the data shows it sends 1 in 10 women to the emergency room. He froze out prolife leaders and repeatedly stonewalled Congress. His resignation is an opportunity for the FDA to reset."
Mifepristone is part of a two-drug cocktail used to terminate pregnancies. Hawley's charge, that Makary slow-walked a review of the drug while simultaneously greenlighting a different abortion drug with troubling safety data, paints a picture of an FDA chief who used procedural discretion to advance outcomes at odds with the administration's stated priorities.
If Hawley's claims hold up, Makary was not merely slow. He was actively working against the coalition that put him in office. That distinction matters.
The administration has faced similar questions about whether appointees are faithfully carrying out the president's directives in other agencies. Recent swirling reports about personnel at the FBI reflect the same underlying tension: how do you run a government when your own people won't row in the same direction?
Newsmax reported that HHS Secretary Robert F. Kennedy Jr. personally decided to move on from Makary after 13 months, with the White House signing off. An administration official told Politico, "It was really Secretary Kennedy himself who made this decision." CBS News separately reported that Trump had approved a plan to remove Makary from his post.
Trump's refusal to say whether he fired Makary leaves the official account ambiguous. But the timeline, a week of removal reports, a direct presidential reprimand, a forced policy reversal, and then a "resignation", speaks for itself.
The Washington Examiner noted that Makary had faced mounting internal and political pressure over fruit-flavored vape approvals, mifepristone policy, and disputes with pharmaceutical companies. Senior officials confirmed that Diamantas, the deputy commissioner for human foods, is expected to step into the senior role temporarily.
The battle over federal vaping approvals dates to the first Trump administration. Youth vaping peaked in 2019, with 27.5% of high school students and 10.5% of middle school students reporting past-month use in the National Youth Tobacco Survey. Trump signed legislation that year raising the minimum purchase age to 21. Flavor options were effectively banned during the COVID-19 pandemic.
By 2025, the federal survey showed 7.1% of high school students and 2.6% of middle schoolers reported past-month vape use, roughly a three-fourths decline among both groups. The numbers suggest the age restriction and enforcement crackdowns worked. That context matters when evaluating whether age-gated technology like the Glas product represents a reasonable next step or a backdoor to hooking kids.
Makary apparently decided it was the latter and slow-walked the approval despite his own agency's published decision. The president disagreed. In the executive branch, that disagreement has a clear resolution mechanism: the president wins.
The episode also illustrates a recurring problem with officials across the administration who treat their appointments as personal fiefdoms rather than delegated authority. A commissioner who blocks his own agency's published approval is not exercising careful judgment. He is substituting his preferences for the policy direction of the elected president.
Makary's departure leaves the FDA at a crossroads. The agency must now navigate pending vape applications, the mifepristone review, and broader drug-pricing reform under acting leadership. Diamantas inherits an agency that Breitbart described as battered by layoffs, leadership upheaval, and complaints from pharmaceutical executives, vaping lobbyists, and anti-abortion activists alike.
The open questions are significant. Will the next permanent commissioner actually implement the administration's agenda on abortion drugs? Will the relaxed vaping enforcement framework survive legal challenge? And will the FDA's institutional culture continue to resist direction from political leadership?
For conservative voters who sent Trump back to Washington expecting results, the Makary saga is a reminder that personnel is policy. Appointing someone with impressive credentials means nothing if that person won't execute the job description.
When your own commissioner blocks your own agency's own approval for months, the resignation isn't the problem. It's the delay that preceded it.
